HLTH - Nobilis Health Corp Stock Price, Fair Value and News

0.15USD0.00 (0.00%)Market Closed

Market Summary

USD0.150.00

Market Closed

0.00%

HLTH Stock Price

View Fullscreen

HLTH RSI Chart

HLTH Valuation

Market Cap

23.8M

Price/Earnings (Trailing)

-0.06

Price/Sales (Trailing)

0.34

EV/EBITDA

0.18

Price/Free Cashflow

-0.16

HLTH Price/Sales (Trailing)

HLTH Profitability

EBT Margin

-519.72%

Return on Equity

-149.24%

Return on Assets

-109.91%

Free Cashflow Yield

-618.15%

HLTH Fundamentals

HLTH Revenue

Revenue (TTM)

70.9M

Rev. Growth (Yr)

-87.19%

Rev. Growth (Qtr)

7.56%

HLTH Earnings

Earnings (TTM)

-373.5M

Earnings Growth (Yr)

-371.12%

Earnings Growth (Qtr)

-216.01%

Breaking Down HLTH Revenue

Last 7 days

7.1%

Last 30 days

-21.0%

Last 90 days

-31.8%

Trailing 12 Months

-84.7%

How does HLTH drawdown profile look like?

HLTH Financial Health

Current Ratio

2.54

HLTH Investor Care

Shares Dilution (1Y)

3.48%

Diluted EPS (TTM)

-2.44

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	328.8M	251.0M	198.9M	70.9M
2022	733.0M	683.3M	529.2M	483.5M
2021	171.7M	320.5M	469.3M	618.1M
2020	0	0	14.8M	23.0M
2019	0	0	0	6.6M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Nobilis Health Corp

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Mar 25, 2024	sever clint	sold (taxes)	-3,886	0.19	-20,456	chief executive officer
Mar 05, 2024	sever clint	sold (taxes)	-3,151	0.25	-12,604	chief product officer
Mar 05, 2024	javed aasim	sold (taxes)	-3,331	0.25	-13,327	chief financial officer
Mar 05, 2024	achar christopher k	sold (taxes)	-2,120	0.25	-8,482	-
Mar 05, 2024	pollard randall e.	sold (taxes)	-1,826	0.25	-7,304	chief accounting officer
Mar 05, 2024	khattak ayub k	sold (taxes)	-2,685	0.25	-10,742	president and ceo
Feb 16, 2024	reddy rishi	acquired	-	-	63,300	-
Feb 08, 2024	khattak ayub k	acquired	-	-	700,000	president and ceo
Feb 08, 2024	javed aasim	acquired	-	-	500,000	chief financial officer
Feb 08, 2024	achar christopher k	acquired	-	-	300,000	-

Which funds bought or sold HLTH recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 23, 2024	Global Retirement Partners, LLC	unchanged	-	-26.00	236	-%
Apr 19, 2024	Financial Perspectives, Inc	unchanged	-	4.00	27.00	-%
Apr 19, 2024	JABODON PT CO	unchanged	-	104,000	751,000	0.54%
Apr 16, 2024	Register Financial Advisors LLC	new	-	45.00	45.00	-%
Apr 12, 2024	Morton Capital Management LLC/CA	unchanged	-	391	2,829	-%
Apr 11, 2024	EXECUTIVE WEALTH GROUP LLC	added	200	8,000	10,288	-%
Apr 11, 2024	PRIVATE CAPITAL MANAGEMENT LLC	unchanged	-	261	1,886	-%
Mar 22, 2024	PNC Financial Services Group, Inc.	sold off	-100	-354	-	-%
Mar 15, 2024	B. Riley Wealth Advisors, Inc.	added	24.62	-62,348	52,650	-%
Mar 11, 2024	VANGUARD GROUP INC	unchanged	-	-1,086,820	631,196	-%

Are Funds Buying or Selling HLTH?

Are funds buying HLTH calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own HLTH

No. of Funds

Unveiling Nobilis Health Corp's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 21, 2024	tarsadia capital, llc	6.9%	10,684,791	SC 13D/A
Feb 14, 2024	khattak ayub k	7.53%	11,636,166	SC 13G/A
Feb 09, 2024	ksp cue health investments, llc	0%	0	SC 13G/A
Oct 16, 2023	oakmont corp	6.3%	9,595,348	SC 13D
Sep 18, 2023	tarsadia capital, llc	6.96%	10,684,791	SC 13D/A
Sep 11, 2023	tarsadia capital, llc	0.1%	100,791	SC 13D
Feb 14, 2023	oakmont corp	6.4%	9,595,348	SC 13G/A
Feb 14, 2023	khattak ayub k	7.6%	11,284,069	SC 13G/A
Feb 10, 2023	ksp cue health investments, llc	8.8%	13,178,383	SC 13G/A
Feb 14, 2022	oakmont corp	6.7%	9,789,997	SC 13G

Recent SEC filings of Nobilis Health Corp

View All Filings

Date Filed	Form Type	Document
Apr 22, 2024	ARS	ARS
Apr 22, 2024	DEF 14A	DEF 14A
Apr 12, 2024	PRE 14A	PRE 14A
Apr 09, 2024	8-A12B/A	8-A12B/A
Apr 09, 2024	8-K	Current Report
Mar 29, 2024	8-K	Current Report
Mar 27, 2024	4	Insider Trading
Mar 20, 2024	8-K	Current Report
Mar 13, 2024	10-K	Annual Report
Mar 13, 2024	8-K	Current Report

Peers (Alternatives to Nobilis Health Corp)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
UNH	449.3B	371.6B	-0.74%	-0.51%	20.08	1.21	14.64%	11.24%
CI	103.0B	195.3B	0.26%	37.72%	19.17	0.53	8.17%	-20.79%
CVS	85.3B	357.8B	-12.72%	-6.73%	10.21	0.24	10.95%	93.52%
HCA	84.4B	65.0B	-3.19%	11.59%	16.11	1.3	7.86%	-7.11%
CNC	40.8B	154.0B	-1.43%	12.08%	15.09	0.26	6.54%	124.79%
DVA	11.6B	12.1B	-0.12%	51.97%	16.83	0.96	4.57%	23.40%
UHS	11.5B	14.3B	-8.62%	17.22%	16.03	0.81	6.59%	6.24%
MID-CAP
CHE	9.3B	2.3B	-4.84%	8.83%	34.26	4.12	6.06%	9.17%
ACHC	6.6B	2.9B	-7.52%	-4.24%	-303.27	2.24	12.20%	-107.93%
AMN	2.2B	3.8B	-10.62%	-35.16%	10.28	0.57	-27.73%	-52.50%
AMEH	2.1B	1.4B	-5.65%	-0.29%	33.83	1.48	21.19%	34.42%
SMALL-CAP
ADUS	1.5B	1.1B	-8.44%	-16.43%	24.79	1.46	11.31%	35.83%
BKD	1.3B	3.0B	7.61%	59.68%	-6.76	0.42	6.74%	20.73%
BEAT	54.0M	-	-3.27%	-3.72%	-3.69	-	-	-12.94%
AMS	18.7M	21.3M	13.26%	5.28%	35.15	0.88	8.00%	-62.25%

Nobilis Health Corp News

Latest updates

Nobilis Health Corp Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2019Q4
Revenue	7.6%	18,798,000	17,477,000	9,896,000	24,765,000	146,777,000	69,589,000	87,700,000	179,410,000	192,506,000	223,679,000	137,423,000	64,499,000	34,614,500	4,730,000	-
Operating Expenses	104.1%	167,703,000	82,182,000	95,289,000	120,615,000	185,401,000	137,002,000	190,163,000	176,562,000	169,125,000	136,304,000	72,715,000	49,744,000	-	13,232,000	-
S&GA Expenses	-11.7%	6,226,000	7,051,000	8,059,000	11,248,000	19,312,000	18,129,000	16,971,000	34,168,000	21,198,000	5,572,000	1,529,000	430,000	-	19,000	-
R&D Expenses	-13.1%	32,248,000	37,103,000	36,536,000	44,733,000	56,149,000	42,516,000	44,000,000	28,787,000	21,679,000	9,079,000	4,662,000	7,409,000	-	6,878,000	-
EBITDA Margin	-321.3%	-4.39	-1.04	-0.93	-0.77	-0.33	-0.20	0.02	0.20	0.25	-0.09	-0.13	-0.24	-1.77	-1.14	-
Interest Expenses	-	-	-	-	-	645,000	-	-	-	9,049,000	-	493,000	267,000	-	-	-
Income Taxes	-98.7%	60,000	4,733,000	-	-	-5,315,000	-1,047,000	-3,386,000	-	-10,615,000	30,098,000	12,050,000	1,226,000	-	-	-
Earnings Before Taxes	-251.3%	-148,372,000	-42,237,000	-83,864,000	-94,198,000	-36,821,000	-67,350,000	-102,436,000	2,803,000	23,615,000	49,446,000	31,859,000	14,257,000	-	-8,538,000	-
EBT Margin	-302.1%	-5.20	-1.29	-1.12	-0.91	-0.42	-0.27	-0.04	0.15	0.19	-0.10	-0.15	-0.28	-2.06	-1.39	-
Net Income	-216.0%	-148,432,000	-46,970,000	-83,864,000	-94,198,000	-31,506,000	-66,303,000	-99,050,000	2,803,000	34,230,000	19,348,000	19,809,000	13,031,000	-	-8,538,000	-
Net Income Margin	-308.2%	-5.26	-1.29	-1.10	-0.89	-0.40	-0.24	-0.06	0.10	0.14	-0.10	-0.15	-0.28	-2.06	-1.39	-
Free Cashflow	-112.0%	-30,090,000	-14,196,000	-44,905,000	-57,789,000	-58,702,000	-52,306,000	-69,831,000	18,739,000	-25,362,000	1,422,000	-28,753,000	-65,604,000	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet											(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2020Q4
Assets	-31.0%	340	492	524	609	695	825	914	984	940	922	316
Current Assets	-42.6%	110	192	212	287	371	522	620	701	670	670	184
Cash Equivalents	-27.4%	81.00	111	129	178	242	305	363	426	410	447	129
Inventory	-77.9%	14.00	64.00	68.00	82.00	82.00	133	139	133	88.00	71.00	37.00
Liabilities	-13.5%	90.00	103	101	113	118	235	274	259	233	268	241
Current Liabilities	-25.6%	43.00	58.00	57.00	67.00	71.00	175	210	192	167	182	156
Shareholder's Equity	-35.6%	250	389	423	496	576	590	640	725	707	654	-101
Retained Earnings	-33.5%	-591	-443	-396	-312	-218	-186	-120	-21.21	-24.02	-58.25	-110
Additional Paid-In Capital	1.2%	842	832	819	808	795	777	761	746	731	713	9.00
Shares Outstanding	0.5%	155	155	153	152	150	147	147	147	53.00	32.00	16.00
Float	-	-	-	50.00	-	-	-	334	-	-	-	-

Cashflow (Last 12 Months)

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Cashflow (Quarterly)															(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2019Q4
Cashflow From Operations	-129.0%	-28.72	-12.54	-42.66	-53.88	-51.70	-39.91	-51.83	32.00	9.00	20.00	-2.70	-35.11	-	-	-
Share Based Compensation	-20.1%	10.00	13.00	12.00	14.00	16.00	16.00	17.00	16.00	17.00	19.00	4.00	3.00	-	-	-
Cashflow From Investing	49.8%	-1.83	-3.66	-5.99	-8.32	-10.09	-18.27	-20.62	-14.05	-37.56	-19.26	-27.05	-31.84	-	-	-
Cashflow From Financing	98.9%	-0.01	-0.90	-1.00	-1.13	-1.87	-0.30	-3.39	-0.87	-6.17	206	163	57.00	-	-	-

HLTH Income Statement

2023-12-31

CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)	12 Months Ended
CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Revenue
Revenue	$ 70,936,000	$ 483,476,000	$ 618,107,000
Operating costs and expenses:
Sales and marketing	32,584,000	88,580,000	28,729,000
Research and development	150,620,000	171,452,000	42,829,000
General and administrative	57,355,000	97,103,000	79,788,000
Impairment of long-lived assets	83,639,000	0	0
Restructuring expense	14,500,000	2,020,000	0
Total operating costs and expenses	465,789,000	689,128,000	427,888,000
(Loss) income from operations	(394,853,000)	(205,652,000)	190,219,000
Interest income	6,240,000	3,328,000	108,000
Interest expense	(1,159,000)	(645,000)	(9,809,000)
Change in fair value of redeemable convertible preferred stock warrants	0	0	53,000
Change in fair value of convertible notes	0	0	(59,560,000)
Loss on extinguishment of debt	0	0	(1,998,000)
Tax credits	20,939,000	0	0
Other income (expense), net	162,000	(835,000)	164,000
Net (loss) income before income taxes	(368,671,000)	(203,804,000)	119,177,000
Income tax expense (benefit)	4,793,000	(9,748,000)	32,759,000
Net (loss) income	$ (373,464,000)	$ (194,056,000)	$ 86,418,000
Net (loss) income per share attributable to common stockholders – basic (in dollars per share)	$ (2.44)	$ (1.31)	$ 0.63
Weighted-average number of shares used in computation of net (loss) income per share attributable to common stockholders – basic (in shares)	152,877,306	148,024,749	52,815,449
Net (loss) income per share attributable to common stockholders – diluted (in dollars per share)	$ (2.44)	$ (1.31)	$ 0.59
Weighted-average number of shares used in computation of net (loss) income per share attributable to common stockholders – diluted (in shares)	152,877,306	148,024,749	59,635,384
Product revenue
Revenue
Revenue	$ 64,223,000	$ 474,166,000	$ 615,796,000
Operating costs and expenses:
Cost of product revenue	127,091,000	329,973,000	276,542,000
Grant and other revenue
Revenue
Revenue	$ 6,713,000	$ 9,310,000	$ 2,311,000

HLTH Balance Sheet

2023-12-31

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 80,889	$ 241,530
Restricted cash	800	800
Accounts receivable, net of allowance for credit losses ($22 and $2,311, respectively)	1,352	18,751
Inventories, net - current	14,039	82,210
Prepaid expenses	8,479	15,728
Other current assets	4,803	12,134
Total current assets	110,362	371,153
Non-current inventories	56,273	25,436
Property and equipment, net	72,096	189,275
Right-of-use assets operating leases	78,519	85,321
Intangible assets, net	19,644	16,867
Other non-current assets	2,893	6,528
Total assets	339,787	694,580
Current liabilities:
Accounts payable	7,705	7,150
Accrued liabilities and other current liabilities	29,300	52,378
Deferred revenue, current	162	1,566
Operating lease liabilities, current	5,142	7,739
Finance lease liabilities, current	1,157	2,362
Total current liabilities	43,466	71,195
Operating leases liabilities, net of current portion	41,640	44,045
Finance lease liabilities, net of current portion	0	849
Other non-current liabilities	4,429	1,997
Total liabilities	89,535	118,086
Commitments and contingencies
Stockholders’ Equity
Common stock, $0.00001 par value; 500,000,000 and 500,000,000 shares authorized, 155,304,764 and 150,406,014 issued and outstanding at December 31, 2023 and December 31, 2022, respectively	2	1
Additional paid-in-capital	841,788	794,567
Accumulated deficit	(591,538)	(218,074)
Total stockholders’ equity	250,252	576,494
Total liabilities and stockholders’ equity	$ 339,787	$ 694,580

About Nobilis Health Corp

Cue Health Inc., a healthcare technology company, designs and develops diagnostic platform for diagnostic tests for individuals, enterprises, healthcare providers and payors, and public health agencies. It offers Cue Integrated Care platform comprising hardware and software components, such as Cue Health Monitoring System consisting of Cue Reader, a portable and reusable reader, Cue Cartridge, a single-use test cartridge, and Cue Wand, a sample collection wand; Cue Data and Innovation Layer, a solution with cloud-based data and analytics capability; Cue Virtual Care Delivery Apps, which include Cue Health App and Cue Enterprise Dashboard; and Cue Ecosystem Integrations and Apps, a solution that allows integrations with third-party applications and sensors. The company also provides COVID-19 testing kits for the Cue Health Monitoring System The company was formerly known as Cue Inc and changed its name to Cue Health Inc. in December 2017. Cue Health Inc. was incorporated in 2010 and is headquartered in San Diego, California.

CEO	Mr. Ayub K. Khattak
WEBSITE	cuehealth.com
INDUSTRY	Healthcare Plans
EMPLOYEES	1515

Nobilis Health Corp Frequently Asked Questions

What is the ticker symbol for Nobilis Health Corp? What does HLTH stand for in stocks?

HLTH is the stock ticker symbol of Nobilis Health Corp. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Nobilis Health Corp (HLTH)?

As of Tue Apr 23 2024, market cap of Nobilis Health Corp is 23.78 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of HLTH stock?

You can check HLTH's fair value in chart for subscribers.

What is the fair value of HLTH stock?

You can check HLTH's fair value in chart for subscribers. The fair value of Nobilis Health Corp is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Nobilis Health Corp is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for HLTH so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Nobilis Health Corp a good stock to buy?

The fair value guage provides a quick view whether HLTH is over valued or under valued. Whether Nobilis Health Corp is cheap or expensive depends on the assumptions which impact Nobilis Health Corp's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for HLTH.

What is Nobilis Health Corp's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Tue Apr 23 2024, HLTH's PE ratio (Price to Earnings) is -0.06 and Price to Sales (PS) ratio is 0.34. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. HLTH PE ratio will change depending on the future growth rate expectations of investors.